This is the third and final part of Dr. Weiss's presentation on "Highlights in Lung Cancer, 2011". After focusing on developments in relatively narrow...
Does it make sense to do molecular testing on early stage lung cancer patients? Dr. Taofeek Owonikoko of Emory University School of Medicine and the...
The Northwest Medical Development Therapeutics Institute is breaking new ground by conducting clinical trials that will test treatments based on tumor...
Progression-free survival is something that doctors measure to determine how well a patient responds to a particular treatment. But does it translate...
How much detail is needed when determining how to treat lung cancer? Should patients be tested for all the mutations that may exist within their...
New treatments for ALK rearrangements are on the horizon. In this video, the doctors discuss how they determine whether or not they change treatments...
Acquired Resistance Forum Video #13: Dr. Jack West of Swedish Cancer Institute discussed how the skyrocketing costs of cancer care are impacting whether or not some patients are able to get the right treatments.
[powerpress]
Dr. Jack West, Dr. Julie Brahmer, and Dr. Ben Creelan discuss the excitement the medical community is feeling about immunotherapy for the treatment of lung cancer. February 2014
[powerpress]
The stigma of lung cancer can lead to shame, fear, and sub-optimal care. Dr. Joan Schiller wants us all to get past it, and she's leading the charge to make that happen. February 2014.
[powerpress]
Does it make sense to do molecular testing on early stage lung cancer patients? Dr. Taofeek Owonikoko of Emory University School of Medicine and the Winship Cancer Institute thinks it does in some settings. February 2014
[powerpress]
The Northwest Medical Development Therapeutics Institute is breaking new ground by conducting clinical trials that will test treatments based on tumor mutations, rather than where the tumor began. Dr. Melissa Johnson describes the work of the center.
[powerpress]
Progression-free survival is something that doctors measure to determine how well a patient responds to a particular treatment. But does it translate to increased overall survival?
[powerpress]
How much detail is needed when determining how to treat lung cancer? Should patients be tested for all the mutations that may exist within their tumors? Dr. Jonathan Riess discusses this issue and how he makes decisions regarding his own patients.
[powerpress]
Why would an ALK lung cancer patient need a repeat biopsy? The doctors discuss the need for and frequency of repeat biopsies.
New treatments for ALK rearrangements are on the horizon. In this video, the doctors discuss how they determine whether or not they change treatments for their patients once they begin to show progression while on Xalkori (crizotinib).
[powerpress]
How often should ALK patients receive scans to determine if their disease has progressed in various parts of the body?
[powerpress]
(IE/Firefox Users: If you have playback problems, please view on YouTube or try the "Download" button above. Get the latest QuickTime Player.)
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.